Maze Therapeutics (NASDAQ: MAZE) exec exercises options, sells shares

Q: Who is the insider in this Maze Therapeutics (MAZE) Form 4 filing?

The insider is Harold Bernstein , who serves as President, R&D & Chief Medical Officer of Maze Therapeutics, Inc. and is a reporting person for this transaction.

Q: What stock option transaction did Harold Bernstein report for Maze Therapeutics (MAZE)?

On January 7, 2026, Harold Bernstein exercised a stock option (right to buy) covering 25,156 shares of Maze Therapeutics common stock at an exercise price of $10.42 per share, increasing his directly held common shares before the related sale.

Q: How many Maze Therapeutics (MAZE) shares did Harold Bernstein sell and at what price?

On January 7, 2026, he sold 25,156 shares of Maze Therapeutics common stock at a weighted average price of $40.2011 per share, with individual sale prices ranging from $40.00 to $40.55 per share.

Q: What are the key vesting terms of Harold Bernstein’s Maze Therapeutics stock option?

The option vested as to 1/4 of the total award on October 3, 2023, and thereafter vested or vests as to 1/48 of the total award on each monthly anniversary, subject to his continued service with Maze Therapeutics on each vesting date.

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Maze Therapeutics executive Harold Bernstein, President, R&D & CMO, reported an option exercise and related share sale. On January 7, 2026, he exercised a stock option for 25,156 shares of common stock at an exercise price of $10.42 per share, converting a previously held derivative position into common stock.

On the same day, he sold the same 25,156 shares of common stock at a weighted average price of $40.2011 per share under a Rule 10b5-1 trading plan adopted on September 29, 2025, leaving him with 0 directly held common shares and 312,407 stock options outstanding. The sale price reflects multiple transactions between $40.00 and $40.55 per share.

Insider Trade Summary

Net Seller: 25,156 shares ($1,011,299)

Net Sell 3 txns

Insider Bernstein Harold

Role President, R&D & CMO

Sold 25,156 shs ($1.01M)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	25,156	$0.00	--
Exercise	Common Stock	25,156	$10.42	$262K
Sale	Common Stock	25,156	$40.2011	$1.01M

Holdings After Transaction: Stock Option (Right to Buy) — 312,407 shares (Direct); Common Stock — 25,156 shares (Direct)

Footnotes (1)

This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.55 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

Form 4 Insider Transactions: What Each Field Means →

01/09/2026 - 04:51 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bernstein Harold

(Last)

(First)

(Middle)

C/O MAZE THERAPEUTICS, INC.

171 OYSTER POINT BOULEVARD, SUITE 300

(Street)

SOUTH SAN FRANCISCO

94080

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President, R&D & CMO

3. Date of Earliest Transaction (Month/Day/Year)
01/07/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/07/2026		M⁽¹⁾		25,156	A	$10.42	25,156	D
Common Stock	01/07/2026		S⁽¹⁾		25,156	D	$40.2011⁽²⁾	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$10.42	01/07/2026		M⁽¹⁾			25,156	⁽³⁾	10/26/2032	Common Stock	25,156	$0	312,407	D

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.55 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

	/s/ Courtney Phillips, as attorney-in-fact	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

Who is the insider in this Maze Therapeutics (MAZE) Form 4 filing?

The insider is Harold Bernstein, who serves as President, R&D & Chief Medical Officer of Maze Therapeutics, Inc. and is a reporting person for this transaction.

What stock option transaction did Harold Bernstein report for Maze Therapeutics (MAZE)?

On January 7, 2026, Harold Bernstein exercised a stock option (right to buy) covering 25,156 shares of Maze Therapeutics common stock at an exercise price of $10.42 per share, increasing his directly held common shares before the related sale.

How many Maze Therapeutics (MAZE) shares did Harold Bernstein sell and at what price?

On January 7, 2026, he sold 25,156 shares of Maze Therapeutics common stock at a weighted average price of $40.2011 per share, with individual sale prices ranging from $40.00 to $40.55 per share.

Was the Maze Therapeutics (MAZE) insider sale made under a Rule 10b5-1 trading plan?

Yes. The filing states that the transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Harold Bernstein on September 29, 2025, which is a pre-arranged trading plan for buying or selling securities.

How many Maze Therapeutics (MAZE) securities does Harold Bernstein hold after these transactions?

Following the reported transactions, Harold Bernstein directly holds 0 shares of Maze Therapeutics common stock and 312,407 stock options (derivative securities), according to the Form 4 tables.

What are the key vesting terms of Harold Bernstein’s Maze Therapeutics stock option?

The option vested as to 1/4 of the total award on October 3, 2023, and thereafter vested or vests as to 1/48 of the total award on each monthly anniversary, subject to his continued service with Maze Therapeutics on each vesting date.